TORONTO, Jan. 16, 2018 /CNW/ - Delivra Corp. (TSXV: DVA -
"Delivra" or the "Company") announced today the Company has
developed a revolutionary, proprietary topical cream base
therapeutic, DelivraTMN, for molecules of Cannabis,
Cannabis-like and opioids, for a safer, more targeted and
consistent delivery to patients afflicted with chronic pain and
anxiety.
"Our goal is to develop innovative products using our
proprietary topical delivery platform (DelivraTM) to
meet significant unmet medical needs and improve quality of life.
With our proven patent-pending technology and formulation
expertise, we have created medical grade products that have shown
significant efficacy and predictable outcomes to patients," said
Dr. Joseph Gabriele, CEO of Delivra.
"With the capability to deliver products on the market immediately
that provide superior efficacy with minimum side effects that are
commercial-ready, Delivra will capitalize on the significant growth
opportunities ahead and advance innovative and alternative
therapeutics to broaden the Company's product offerings."
According to Health Canada Statistics, 1 in 5 Canadians from
ages 12-44 suffer from chronic pain, representing a significant
unmet medical need to improve treatments for patients. The Canadian
Pain Society identifies chronic pain as an expensive
problem, not only to the patient, but also society in general.
The traditional treatments cost billions of dollars a year in
health costs, lost productivity, and social costs to lives
that are further derailed by addiction or depression.
According to National report by the Federal Government of
Canada, the Canadian opioid
related death rate is 8.8 per 100,000 population.
DelivraTMN, meets the growing need for specialized
products with alternative delivery mechanisms for treating patients
with less side-effects than inhalation, needles and oral methods of
drug delivery. Specifically, FDA-approved cannabis-like molecules
such as nabilone, and a safer opioid molecule, buprenorphine, are
combined and formulated with the Company's patent-pending
DelivraTMN base; that have been successfully tested in
human pain clinics and have demonstrated to help in numerous
chronic pain patients to manage their symptoms. As a partner with
the National Research Council of
Canada, Delivra takes a strict
regulatory approach by testing all formulations in the Company's
formulation laboratory and analytical facility including
pre-clinical and clinical testing, to maximize the efficacy and
benefits to the patient.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company that has a
proprietary transdermal delivery system platform that can shuttle
pharmaceutical and natural molecules through the skin in a targeted
specific manner. Delivra manufactures and sells a growing line of
natural topical creams with the proprietary transdermal delivery
system platform under the LivReliefTM brand, for
conditions such as joint and muscle pain, nerve pain, varicose
veins, wound healing, and under the LivSportTM brand for
sports performance. LivReliefTM products are available
in pharmacies, grocery chains, and independent health food stores
across Canada, and on-line at
www.livrelief.com. In parallel with its consumer products business,
Delivra also has a mandate to license its patent-pending
proprietary transdermal delivery technology platform to
pharmaceutical companies globally, for the repurposing of
pharmaceutical molecules transdermally to treat a broad range of
conditions, along with licensing its over-the-counter products
globally. Delivra is headquartered in Hamilton, Ontario and has a research and
development laboratory in Charlottetown, PEI.
Further information on Delivra can be found at
www.delivracorp.com, www.livrelief.com for Canada and www.livrelief.com/us for
the United States.
Cautionary Note Regarding Forward-Looking Statements
This news release includes certain information and statements
about management's view of future events, expectations, plans and
prospects that constitute "forward-looking statements", which are
not comprised of historical facts. Forward-looking statements may
be identified by such terms as "believes", "anticipates",
"intends", "expects", "estimates", "may", "could", "would", "will",
or "plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the Company's drug research and development
plans; the timing of operations; and estimates of market
conditions. These statements involve known and unknown risks,
uncertainties, and other factors that may cause actual results or
events, performance, or achievements of Delivra to differ
materially from those anticipated or implied in such
forward-looking statements. The Company believes that the
expectations reflected in these forward-looking statements are
reasonable, but there can be no assurance that actual results will
meet management's expectations. In formulating the forward-looking
statements contained herein, management has assumed that business
and economic conditions affecting Delivra will continue
substantially in the ordinary course and will be favorable to
Delivra, that clinical testing results will justify
commercialization of the Company's drug candidates; that Delivra
will be able to obtain all requisite regulatory approvals to
commercialize its drug candidates, that such approvals will be
received on a timely basis, and that Delivra will be able to find
suitable partners for development and commercialization of its
products and intellectual property on favourable terms. Although
these assumptions were considered reasonable by management at the
time of preparation, they may prove to be incorrect. Factors that
may cause actual results to differ materially from those
anticipated by these forward-looking statements include:
uncertainties associated with obtaining regulatory approval to
perform clinical trials and market products; the need to establish
additional corporate collaborations, distribution or licensing
arrangements; the ability of the Company to generate sales and
profits; the Company's ability to raise additional capital if and
when necessary; intellectual property disputes; increased
competition from pharmaceutical and biotechnology companies;
changes in equity markets, inflation, and changes in exchange
rates; and other factors as described in detail in Delivra's public
filings, all of which may be viewed on SEDAR (www.sedar.com). Given
these risks and uncertainties, readers are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
Except as required by law, Delivra disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE Delivra Corp